Category: Arch Therapeutics
Arch Therapeutics hits its $2.9 million funding goal after announcing a private stock placement late last year.
Arch Therapeutics hit its nearly $2.9 million target with a private placement announced late last year.
Massachusetts-based Arch Therapeutics hopes to sell over 11 million shares to raise close to $3 million in support of its medical sealants and hemostasis products.
Arch Therapeutics launched a private placement fundraising effort, offering 11.4 million shares of common stock in hopes of raising $2.9 million.
Arch Therapeutics reports a $7.3 million financing through a share-swap related to its reverse merger with Arch Biosurgery, which marked the Arch Therapeutics’ transformation into a life sciences company.
Cambridge, Mass.-based device company Arch Therapeutics raised $7.3 million through a stock trade in connection with its reverse merger with Arch Biosurgery.
Arch Therapeutics issued shares of its common stock in exchange for cancellation of equity or rights to acquire equity in Arch Biosurgery, according to a regulatory filing.
Breast reconstruction technology company AirXpanders is almost halfway to a hoped-for $9M funding round.
A new finance chief will take over on Monday at Becton Dickinson & Co. (NYSE:BDX), the company announced this week. BD nabbed Christopher Reidy from his former gig as CFO at ADP Corporation. Reidy has also worked in executive finance roles at NBA Properties Inc. and AT&T.
Following a reverse-merger with Arch Biosciences, Arch Therapeutics names a new CEO, board chairman and director.
Three fresh faces are taking over at Arch Therapeutics following the blood management device company's reverse merger with Arch Biosurgery. Last last month Arch Therapeutics turned over a new leaf as a life science company after adopting the business plan of newly acquired subsidiary Arch Biosurgery.
Shortly after closing the deal, Arch Therapeutics cleaned out its management team, appointing a new CEO, board chairman, and company director.